A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells.
Several barriers exist to high-efficiency transfer of therapeutic genes into human hematopoietic stem cells (HSCs) using complex oncoretroviral vectors. Human clinical trials to date have used Moloney leukemia virus-based amphotropic and gibbon ape leukemia virus-based envelopes in stable retroviral packaging lines. However, retroviruses pseudotyped with these envelopes have low titers due to the inability to concentrate viral supernatants efficiently by centrifugation without damaging the virus and low transduction efficiencies because of low-level expression of viral target receptors on human HSC. The RD114 envelope from the feline endogenous virus has been shown to transduce human CD34+ cells using transient packaging systems and to be concentrated to high titers by centrifugation. Stable packaging systems have potential advantages over transient systems because greater and more reproducible viral productions can be attained. We have, therefore, constructed and tested a stable RD114-expressing packaging line capable of high-level transduction of human CD34+ cells. Viral particles from this cell line were concentrated up to 100-fold (up to 10(7) viral particles/ml) by ultracentrifugation. Human hematopoietic progenitors from cord blood and sickle cell CD34+ cells were efficiently transduced with a Neo(R)-containing vector after a single exposure to concentrated RD114-pseudotyped virus produced from this cell line. Up to 78% of progenitors from transduced cord blood CD34+ cells and 51% of progenitors from sickle cell CD34+ cells expressed the NeoR gene. We also show transfer of a human beta-globin gene into progenitor cells from CD34+ cells from sickle cell patients with this new RD114 stable packaging system. The results indicate that this packaging line may eventually be useful in human clinical trials of globin gene therapy.
Department of Genetics and Development, Columbia University, New York, New York 10032, USA.
Maureen
M
Ward
Rose
R
Sattler
I Robert
IR
Grossman
Anthony J
AJ
Bell
Donna
D
Skerrett
Laxmi
L
Baxi
Arthur
A
Bank
D036541:ADP-ribosyl Cyclase / Q000096:biosynthesis; D051997:ADP-ribosyl Cyclase 1; D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D002460:Cell Line; D002469:Cell Separation; D002498:Centrifugation; D005312:Fetal Blood / Q000166:cytology; D005434:Flow Cytometry; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005914:Globins / Q000235:genetics; D006367:HeLa Cells; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D008562:Membrane Glycoproteins; D008747:Methylcellulose / Q000378:metabolism; D051379:Mice; D008957:Models, Genetic; D041681:NIH 3T3 Cells; D016133:Polymerase Chain Reaction; D012190:Retroviridae / Q000235:genetics*; D012805:Sickle Cell Trait; D013997:Time Factors; D014161:Transduction, Genetic
D015703:Antigens, CD; D018952:Antigens, CD34; D008562:Membrane Glycoproteins; D005914:Globins; D008747:Methylcellulose; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; C498155:Cd38 protein, mouse; D051997:ADP-ribosyl Cyclase 1